Akebia Therapeutics is entering a show-me phase as Vafseo adoption accelerates, but profitability remains distant amid Auryxia's decline and rising costs. Vafseo's observed dosing protocol is driving ...
Akebia’s EPS missed forecasts by 200%, with a significant impact on investor sentiment. Revenue declined by 6.6% year-over-year, driven by falling AURYXIA sales. Vafseo sales showed strong growth, ...
"We are very pleased and excited by the start to 2026" (CEO, President & Director John Butler), highlighting three execution priorities: "drive the near-term launch performance of Vafseo," "continue ...
Akebia missed both EPS and revenue forecasts for Q1 2026. The company’s stock fell nearly 19% in premarket trading. Vafseo revenues showed strong growth, up 31.7% year-over-year. Auryxia revenues ...
Detailed price information for Akebia Therapeutics (AKBA-Q) from The Globe and Mail including charting and trades.
"Vafseo commercial trends are showing marked improvement in early 2026, built on the solid foundation we created for the brand in its first year of launch,” said John P. Butler, Chief Executive ...
Akebia Therapeutics (NASDAQ:AKBA) posted $62.5 million in GAAP revenue for Q2 2025. GAAP revenue was $47.2 million, missing analyst estimates of $47.24 million. Net income (GAAP) reached $0.2 million, ...
On July 9, 2021, in Karth v. Keryx Biopharmaceuticals, Inc., the U.S. Court of Appeals for the First Circuit affirmed entry of judgment for the defendants in a putative class action asserting ...
Please provide your email address to receive an email when new articles are posted on . Akebia Therapeutics has filed a lawsuit against CMS for rescinding Medicare Part D coverage of the company’s FDA ...
Akebia Therapeutics, a small Cambridge, Mass.-based drugmaker, has filed a lawsuit against CMS, claiming Medicare’s denial to cover its anemia drug violates the law, according to STAT. Akebia’s only ...
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency ...
disclosed Thursday that his long-term stake in kidney care company Keryx Biopharmaceuticals closed as it converted into a stake in Akebia Therapeutics upon the merger of the two companies. Klarman’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results